Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

durvalumab 3Specimen Handling 3Oxaliplatin 3Leucovorin 3Magnetic Resonance Spectroscopy 2Gemcitabine 2Folfox protocol 2Fluorouracil 2Cisplatin 2Biopsy 2zanidatamab 1trastuzumab deruxtecan 1peposertib 1pembrolizumab 1guadecitabine 1fludarabine 1dehydroftorafur 1binimetinib 1avelumab 1Radiation Dose Hypofractionation 1Radiation 1Paclitaxel 1Nivolumab 1Irinotecan 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × guadecitabine × 30 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡